1. Phosphorylated Smad2 in Advanced Stage Gastric Carcinoma
- Author
-
Naoshi Kubo, Osamu Shinto, Hiroaki Tanaka, Yosuke Doi, Masakazu Yashiro, Taro Matsuzaki, Tetsuji Sawada, Masaichi Ohira, Satoru Noda, Ryoji Kaizaki, Takahiro Toyokawa, Takafumi Nishii, Kosei Hirakawa, and Kazuya Muguruma
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Cancer Research ,Time Factors ,SMAD ,Kaplan-Meier Estimate ,Smad2 Protein ,Adenocarcinoma ,Risk Assessment ,lcsh:RC254-282 ,Peritoneal Neoplasm ,Japan ,Surgical oncology ,Risk Factors ,Stomach Neoplasms ,medicine ,Genetics ,Humans ,Neoplasm Invasiveness ,Phosphorylation ,Peritoneal Neoplasms ,Neoplasm Staging ,Proportional Hazards Models ,Chi-Square Distribution ,Paraffin Embedding ,business.industry ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunohistochemistry ,Oncology ,Lymphatic Metastasis ,Cancer cell ,Female ,business ,Transforming growth factor ,Research Article - Abstract
Background Transforming growth factor β (TGFβ) receptor signaling is closely associated with the invasion ability of gastric cancer cells. Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma. The aim of the current study is to clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages. Methods Immunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens from 135 patients with advanced gastric adenocarcinomas. We also evaluated the relationship between the expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas. Results The p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas. The p-Smad2 expression level was significantly higher in diffuse type carcinoma (p = 0.007), tumours with peritoneal metastasis (p = 0.017), and tumours with lymph node metastasis (p = 0.047). The prognosis for p-Smad2-high patients was significantly (p = 0.035, log-rank) poorer than that of p-Smad2-low patients, while a multivariate analysis revealed that p-Smad2 expression was not an independence prognostic factor. Conclusion The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.
- Published
- 2010